A new drug that has the potential to transform the face, scalp and hair cosmetics industry is still used by hundreds of thousands of people around the world, despite an international embargo on its sale.

According to research published in the British Journal of Dermatology, elexyl, a synthetic form of benzyl benzoate, is still widely used in cosmetic and personal care products, even though it has been banned by the World Health Organization (WHO) for its harmful effects on the immune system.

“It is an important ingredient in a large number of products including nail polish, shaving cream, shampoo, conditioners and even skin care products,” Dr. Rachael N. Loughlin, the senior scientist at the Royal Free London Hospitals NHS Foundation Trust, told CNN.

“It is a common ingredient in all of these products and its use has been widespread.”

Elexyl is an antibiotic that works by blocking bacterial growth in the skin and scalp.

It is a commonly used antibiotic and has been used in some cosmetics since it was introduced in 1858.

It was used by the French physician Jules Proust, who in 1868 published his first book on his use of the drug in the treatment of acne.

But the drug is still often used by people who do not have any dermatological conditions.

“There are no controlled studies that show its safety or effectiveness,” said Loughly.

“We have seen it for many years in many other products and cosmetics.”

The study is based on the use of elexal and a similar synthetic form called cephalosporin in cosmetic products in the United States.

The researchers examined the efficacy and safety of eylacin and cephosporins in two groups of patients.

They measured the effectiveness of the two compounds, cephelosporinoside and cephosporinoide, in controlling acne and its complications.

The two compounds have the same active ingredients but they have different molecular structure, so they work differently.

The research shows that the two drugs work differently in that they are metabolized differently, and they are not effective at controlling acne, Loughy said.

“This is not to say that these compounds are bad,” she said.

“But there are differences between the two molecules that can cause some differences in efficacy and tolerability.”

According to the researchers, cephosaquinones, the two active ingredients of eylanil, do not interfere with the activity of the peptide-specific enzymes involved in the breakdown of the antibiotics.

They also did not inhibit the activity or activity of a protein that converts cepheline to a metabolite that can be metabolized by the immune cells.

The enzyme that converts eylanlone to cepherone is called cefa-1.

Cefa1 is a transcription factor that is important for the conversion of cepha-1 to ceph-1 in the body, Lougly said.

It controls the enzyme that breaks down cepholosine into cepa-2, a metabolized metabolite of cepha-3.

The body can then use this cephomec to produce cephcid, which is an active ingredient in some products.

The researchers also found that the cephomesinase inhibitors, a class of drugs called C-reactive protein (CRP), that can block the activity and activity of Cefa2, are also ineffective at stopping the growth of fungi and bacteria in the gut.

The study also shows that in patients who do have symptoms of acne, eylanils inhibitors can reduce their symptoms.

“These are very positive findings,” said Dr. Janna Dolan, a dermatologist and associate professor of dermatology at the University of Washington.

“These are exciting results and very important findings because there is no evidence that these drugs are safe or effective in treating acne.”

The researchers hope that their study will lead to the development of a more comprehensive understanding of how to use these drugs in the face and scalp cosmetics industry.

“The goal is to develop new drugs that are safe and effective for use in cosmetics, and then we will be able to develop these drugs for other dermatological problems,” said Dolan.

“This is the ultimate hope.”